Patents
Literature
19 results about "Artificial antigen presenting cells" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Artificial antigen presenting cells (aAPCs) are a new technology and approach to cancer immunotherapy. Immunotherapy aims to utilize the body’s own defense mechanism—the immune system—to recognize mutated cancer cells and to kill them the way the immune system would recognize and kill a virus. Antigen presenting cells are the sentinels of the immune system and patrol the body for pathogens. When they encounter foreign pathogens, the antigen presenting cells alert the T cells—“the soldiers of the immune system”—that there is something foreign in the body with specific cell surface molecules. aAPCs are synthetic versions of these sentinel cells and are made by attaching the specific T-cell stimulating signals to various macro and micro biocompatible surfaces. This can potentially reduce the cost while allowing control over generating large numbers of functional pathogen-specific T cells for therapy. Activated and stimulated T cells can be studied in this biomimetic contex and used for adoptive transfer as an immunotherapy.
Scaffolds with stabilized MHC molecules for immune-cell manipulation
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.
Owner:DANMARKS TEKNISKE UNIV
Surface-functionalized microgels and uses thereof for t cell expansion
PCT designated stageWO2025226726A1Cell culture supports/coatingBlood/immune system cellsCell phenotypeActivation cells
The present disclosure relates, at least in part, to compositions comprising microgels and / or granular hydrogels with tailored surface biochemical properties that can serve, e.g., as artificial antigen-presenting cells (aAPCs) to mediate, e.g., T cell activation and expansion. Such microgels and / or granular hydrogels can be used to manufacture T cells for adoptive therapy in cancer treatment and tissue regeneration, and can be configured to serve, e.g., as a readily tunable and modular system to enable both rapid T cell expansion and control over T cell phenotype. Some aspects of the present disclosure provide methods and compositions for fabricating microgels and / or granular hydrogels, and modulating the surface properties of microgels and / or granular hydrogels by functionalizing, e.g., via layer- by-layer coating.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Injectable artificial antigen-presenting cells for immunotherapy
In various aspects and embodiments, this disclosure provides artificial antigen-presenting cells (aAPCs) suitable for parenteral administration for immunotherapy. In various embodiments, aAPCs effectively activate or inhibit target T cells, including CD8+ or CD4+ T cells, in vivo. The aAPCs according to this disclosure provide a storage-stable nanoparticle platform for immunotherapy. In various embodiments, the storage-stable nanoparticle platform controls characteristics such as particle size and particle chemistry, ligand design and ligand density, and aAPC aggregation tendency.
Owner:SERCOURI CO LTD
Method for in vitro mass proliferation and culture of inkt cells without need for artificial antigen-presenting cells
PCT designated stageWO2025173842A1Immunoglobulin superfamilyAntipyreticPeripheral blood mononuclear cellAntiendomysial antibodies
The present invention relates to a method for mass proliferation and culture of iNKT cells, iNKT cells produced by the method, and uses thereof, the method comprising the steps of: expanding iNKT cells from peripheral blood mononuclear cells; and mass-proliferating and culturing the iNKT cells by treating same with an anti-CD28 antibody, the CD40 protein, and an anti-TCR Vα24-Jα18 antibody. Since the method for mass proliferation and culture of the present invention can produce iNKT cells while maintaining an excellent proliferation rate and purity without artificial antigen-presenting cells, the method can be effectively utilized in related technical fields such as treatment of cancer or inflammatory diseases using iNKT cells.
Owner:BIO SOLUTION CO LTD
Synthetic viscoelastic activated cells for t cell engineering
Conventional CAR-T cell therapies have shown a significant success in the treatment of hematological cancers and lymphoma. However, this technique still has several problems, including cancer recurrence. Herein, a scalable technical platform is described to produce synthetic viscoelastic activated cells (SynVAC) with programmable mechanical and chemical activity as artificial antigen presenting cells (aAPC). The disclosure presented herein shows that the viscoelastic properties of the described SynVAC have great beneficial effects on expansion of T cells. For example, SynVAC exhibits robust improvements in T cell expansion, T memory stem cell (TMSC) formation, chimeric antigen receptor (CAR) transduction efficiency, tumor killing efficiency, and long-term in vivo persistence of CAR-T cells compared to conventional rigid or elastic microspheres.
Owner:RGT UNIV OF CALIFORNIA
Nanoparticles for delivery of immunoregulatory materials to t cells
PendingUS20260061054A1Antibody mimetics/scaffoldsGenetically modified cellsDiseaseMajor histocompatibility
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
Owner:JOHNS HOPKINS UNIVERSITY
Scaffolds with stabilized MHC molecules for immune-cell manipulation
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearance. In particular, the scaffolds of the present invention comprise stabilized MHC class I molecules comprising a heavy chain comprising an alpha-1 domain and an alpha-2 domain connected by a disulfide bridge, wherein said MHC class I molecules are free of antigenic peptide. The scaffolds can be loaded with antigenic peptide on demand, providing an agile platform for effective expansion and functional stimulation of specific T cells in a peptide-MHC-directed fashion.
Owner:DANMARKS TEKNISKE UNIV
Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
PCT designated stageWO2026050217A2Genetically modified cellsMammal material medical ingredientsCD86Costimulatory Molecule
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC
Preparation method and application of vesicle vaccine based on chitosan antigen delivery system
PendingCN121102468AAntibody medical ingredientsImmunological disordersChitosan nanoparticlesSodium phosphates
The invention discloses a preparation method and application of a vesicle vaccine based on a chitosan antigen delivery system, the vesicle vaccine stimulates cells to secrete the vesicle vaccine with an antigen presentation function, and the method related to the system specifically comprises the following steps: step 1, mixing antigen protein with a chitosan aqueous solution and a sodium tripolyphosphate aqueous solution, and carrying out electrostatic interaction to obtain a vesicle vaccine solution; chitosan nanoparticles loaded with the antigen protein are prepared; and 2, treating immune cells by using the antigen-loaded chitosan nanoparticles, collecting cell culture supernatant, and collecting and preparing vesicles by adopting a method of combining multi-step differential centrifugation with ultrafiltration. After the antigen delivery system based on chitosan is co-incubated with cells, antigen protein can be effectively delivered into immune cells, meanwhile, the immune cells are promoted to generate a large number of antigen-related vesicles with efficient immunogenicity through the adjuvant effect and autophagy regulation effect of chitosan, and the immunogenicity of the antigen-related vesicles is improved. The application potential of the artificial antigen presenting cell is realized.
Owner:LIANGZHU LAB
Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion
In some embodiments, compositions and methods re¬lating to isolated artificial antigen presenting cells (aAPCs) are dis¬closed, including aAPCs comprising a myeloid cell transduced with one or more viral vectors, such as a MOLM-14 or a EM-3 myeloid cell, wherein the myeloid cell endogenously expresses HLA-A / B / C, ICOS-L, and CD58, and wherein the one or more viral vectors com¬prise a nucleic acid encoding CD86 and a nucleic acid encoding 4-1BBL and / or OX40L and transduce the myeloid cell to express CD86 and 4-1BBL and / or OX40L proteins. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs and methods of treating cancers using TILs after expansion with aAPCs are also disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC
Nanoparticles for delivery of immunoregulatory materials to t cells
Artificial antigen presenting cells (aAPC) including a major histocompatibility class II (MHC II) molecule and methods of their use for identifying, isolating, or detecting one or more antigen-specific T cells, and treating a disease, disorder, or condition, including cancer, are disclosed.
Owner:JOHNS HOPKINS UNIVERSITY
Engineered artificial antigen presenting cells and lipid nanoparticles for tumor infiltrating lymphocyte expansion
PCT designated stageWO2026050217A3Genetically modified cellsMammal material medical ingredientsAntigenCD86
In some embodiments, compositions and methods relating to isolated artificial antigen presenting cells (aAPCs) are disclosed, including aAPCs comprising a U937 cell modified to express one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. Further provided are lipid nanoparticles (LNPs) conjugated to one or more co-stimulatory molecules including CD64, CD86, 4-1BBL and / or OX40L. In some embodiments, methods of expanding tumor infiltrating lymphocytes (TILs) with aAPCs or LNPs and methods of treating cancers using TILs after expansion with aAPCs or LNPs are also disclosed.
Owner:IOVANCE BIOTHERAPEUTICS INC
Artificial antigen-presenting cells and methods for producing and using the same
ActiveUS12478688B2Peptide/protein ingredientsNanomedicineAutologous immune enhancement therapyTolerance induction
Described herein are biomimetic Janus particles useful as artificial antigen presenting cells capable of activating T cells in vitro. “Bull's eye” ligand patterns mimicking either the native or reverse organization of the T cell immunological synapse are provided on the surface of nano- or micro-sized particles. Methods for activating T cells in vitro using biomimetic Janus particles described herein are also provided. T cells activated by the biomimetic Janus particles can be used in adoptive immunotherapies for treating cancer, tolerance induction in autoimmune disease, autologous immune enhancement therapy, and viral infection immunotherapy. Also described herein are methods for producing a biomimetic Janus particle.
Owner:INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORP
Artificial antigen presenting cell based on polymer nanosheet as well as preparation method and application of artificial antigen presenting cell
PendingCN120535642AAntibody ingredientsImmunoglobulins against cell receptors/antigens/surface-determinantsSpecific immunityClick chemistry
The invention relates to the technical field of nano materials and immunity, and provides an artificial antigen presenting cell based on a polymer nanosheet as well as a preparation method and application of the artificial antigen presenting cell. According to the preparation method of the artificial antigen presenting cell, uniform distribution of an N3 group on a two-dimensional polymer nanosheet is realized through a crystallization-driven self-assembly process, then an antibody is subjected to DBCO group modification, and finally the two-dimensional polymer nanosheet is modified with the antibody through a click chemical reaction to form the artificial antigen presenting cell. The interaction with the T cells is realized, and the T cells are activated and amplified. According to the invention, the two-dimensional polymer nanosheet is used as an artificial antigen presenting cell for activating the T cell, and the nanosheet structure effectively increases the contact area between the antibody and the T cell, so that a strong specific immunoreaction can be generated, and an anti-tumor effect is achieved; and the material has the advantages of controllable size, uniform morphology, stable structure, high biocompatibility, biodegradability and the like.
Owner:SHANGHAI UNIV
Method for expansion of double negative regulatory T cells
There is provided herein a method for expanding human CD4−CD8− regulatory T cells (DN Tregs) from a population of cells comprising DN Tregs, comprising: culturing the population of cells with artificial antigen presenting cells (APCs), preferably the DN Tregs are αβ-TCR+CD56− or alternatively γδ-TCR+.
Owner:UNIV HEALTH NETWORK
Methods for identifying functional neoantigens and their use in cancer immunotherapy
PCT designated stageWO2026035444A8Biological material analysisAntineoplastic agentsAdoptive cellular therapyOncology
Disclosed are methods for identifying functional neoantigen peptides and using them in cancer immunotherapy. Candidate HLA-restricted peptides are derived e.g., from tumor mutations, loaded onto paramagnetic nano-artificial antigen-presenting cells (nano-aAPCs) that provide peptide- HLA (signal 1) and costimulatory ligands (signal 2), incubated with T cells, magnetically enriched, expanded in culture, and characterized for antigen specificity, phenotype, and function to select therapeutic peptides. The workflow supports peptide cocktails across Class I / IIHLA presentation for heterozygous subjects, and a wide binding¬ affinity range. Resulting T-cell products are enriched for central / effector memory and polyfunctional responses. The methods enable vaccines, polymeric aAPC therapeutics, adoptive cell therapies, and TCR- based biologies (e.g., bispecific T-cell engagers).
Owner:CELLKURE INC
Artificial antigen presenting cells comprising protein L for expanding immune cells for immunotherapy
Disclosed herein are methods of expanding immune cells for immunotherapy and / or increasing the purity of a population of CAR T cells using artificial antigen presenting cells (aAPCs) having on their surface Protein L. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1 / PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
Owner:H LEE MOFFITT CANCER CENT & RES
Artificial antigen presenting cells comprising protein l for expanding immune cells for immunotherapy
PendingUS20250388860A1Bacterial antigen ingredientsGenetically modified cellsPeripheral blood mononuclear cellMolecular binding
Disclosed herein are methods of expanding immune cells for immunotherapy and / or increasing the purity of a population of CAR T cells using artificial antigen presenting cells (aAPCs) having on their surface Protein L. The disclosed aAPCs can also secrete antibodies that bind molecules of the T cell inhibitory pathway. For example, anti-CD3 scFv on the surface of the aAPCs can bind and activate T cells, while anti-CD28 scFv and 4-1BBL on the surface of the aAPCs can provide dual co-stimulation for the T cells resulting in decreased levels of the markers CD25, TIM3, LAG3, and PD1. For example, blocking PD1 / PDL1 ligation can limit suppression that is mediated by the tumor microenvironment. This is a less costly and more efficient alternative to peripheral blood mononuclear cells (PBMCs) and cytokine treatments that result in better quality T cell for adoptive transfer back into patients.
Owner:H LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE INC
Method for in vitro mass proliferation and culturing of vδ1 t cells without need for artificial antigen-presenting cells
PCT designated stageWO2025220807A1Mammal material medical ingredientsBlood/immune system cellsT cellProliferation rate
The present invention relates to a method for mass proliferation and culturing of Vδ1 T cells, Vδ1 T cells produced by the method, and a use thereof, the method comprising a step for activating lymphocytes from a biological sample containing the lymphocytes, a step for isolating Vδ1 T cells from the activated cell population, and a step for proliferating and culturing the isolated Vδ1 T cells by treating the isolated Vδ1 T cells with an anti-TCRVδ1 antibody. The method for mass proliferation and culturing according to the present invention makes it possible to produce Vδ1 T cells without artificial antigen-presenting cells, while maintaining an excellent proliferation rate and purity, and thus can be effectively used in related technical fields such as cancer treatment using Vδ1 T cells.
Owner:BIO SOLUTION CO LTD